0000899243-23-007009.txt : 20230303
0000899243-23-007009.hdr.sgml : 20230303
20230303170029
ACCESSION NUMBER: 0000899243-23-007009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230301
FILED AS OF DATE: 20230303
DATE AS OF CHANGE: 20230303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRATTAROLI JOSEPH
CENTRAL INDEX KEY: 0001272668
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39676
FILM NUMBER: 23705373
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001750149
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
BUSINESS PHONE: 678-392-3419
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-01
0
0001750149
Inhibikase Therapeutics, Inc.
IKT
0001272668
FRATTAROLI JOSEPH
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA
GA
30339
0
1
0
0
Cheif Financial Officer
Common Stock
48091
D
Stock Option (right to buy)
0.74
2023-03-01
4
A
0
90000
0.00
A
2023-03-01
Common Stock
90000
90000
D
One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date.
/s/ Joseph Frattaroli
2023-03-03